Surface-functionalized iron phosphide nano-particle, nano-drug containing surface-functionalized iron phosphide nano-particle as well as preparation method and application of surface-functionalized iron phosphide nano-particle

Through surface functionalized nanodrugs coated with iron phosphide nanoparticles and microglia exosomes, the problems of drug resistance and treatment accuracy in brain glioma treatment have been solved, and the efficacy and safety have been significantly improved, achieving Effective targeted treatment of drug-resistant tumors.

CN119033959AActive Publication Date: 2024-11-29TSINGHUA UNIVERSITY +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411203814.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-29
Estimated Expiration
2044-08-29

AI Technical Summary

Technical Problem

The existing treatment methods for brain glioma, especially for drug-resistant tumors, are not effective. Traditional drugs such as temozolomide are ineffective in some patients, and it is difficult to accurately target tumor tissue during the treatment process, resulting in healthy tissues. harm.

Method used

By preparing surface-functionalized iron phosphide nanoparticles, combined with microglia-derived exosome coating, a nanodrug was designed to reduce the glutathione concentration and MGMT protein expression in tumor cells and inhibit HPRT1 activity , and enhance the killing ability of drug-resistant brain glioma cells through photothermal conversion, achieving targeted drug delivery.

Benefits of technology

It significantly improves the efficacy of drug-resistant tumors, reduces the generation of drug resistance, enhances the survival rate of TMZ-resistant mice, reduces the harm to healthy tissues, and improves the accuracy and safety of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033959A_ABST
    Figure CN119033959A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of nano biomedical materials, and relates to a surface-functionalized iron phosphide nano-particle, a nano-drug containing the surface-functionalized iron phosphide nano-particle as well as a preparation method and application of the surface-functionalized iron phosphide nano-particle. The preparation method of the surface-functionalized iron phosphide nano-particles comprises the following steps: obtaining surface-sulfhydrylated iron phosphide nano-particles by using iron phosphide nano-particles and molecules containing sulfydryl and other groups capable of being coordinated with iron, and reacting the surface-sulfhydrylated iron phosphide nano-particles with active ingredients containing sulfydryl to obtain the surface-functionalized iron phosphide nano-particles. The nano-drug is prepared from the iron phosphide nano-particles with the functionalized surfaces and an exosome. After the iron phosphide nanoparticles are subjected to surface modification and further prepared into the nano-drug, the nano-drug can reach brain tissues in a targeting manner, and a plurality of ways are cooperated, so that the curative effect on tumors (especially temozolomide drug-resistant tumors) is remarkably improved, and meanwhile, the nano-drug has good biological safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of nano biomedical materials, and relates to surface functionalized iron phosphide nanoparticles and nano medicine containing the same, as well as a preparation method and application thereof. Background Art

[0002] Glioblastoma is the most common primary malignant tumor of the central nervous system in adults in the world, with an incidence of about 3-6.4 / 100,000 people per year. The incidence of grade IV glioblastoma (GBM) specified by the World Health Organization (WHO) is about 4.03 / 100,000 people, accounting for 49.1% of all primary malignant central nervous system tumors. At present, the standard treatment for glioma is the Stupp treatment regimen, which combines surgical resection of the tumor, radiotherapy and adjuvant temozolomide (TMZ) oral chemotherapy, which increases the median survival of glioblastoma patients to 16 months. Although such a treatment regimen can prolong survival time, the overall prognosis of GBM is still poor, and most clinical data show that the five-year survival rate of patients is still less than 10%. At present, TMZ is the only effective oral chemotherapy drug for the treatment of glioma, but at least 50% of patients do not respond to TMZ, and nearly all patients will still show signs of tumor recurrence after receiving standard treatment.

[0003] TMZ induces cell cycle arrest and apoptosis by producing diazomethane to induce methylation of specific sites of guanine and adenine in genomic DNA. Studies have shown that TMZ resistance is not caused by a single molecular event, but by multiple events. It is currently widely recognized that TMZ resistance is related to the expression levels of DNA alkylation proteins and DNA repair enzymes. 6 -Methylguanine DNA methyltransferase (MGMT) plays a key role. MGMT overexpressed in tumor cells can remove the methyl group at this site and repair the DNA damage caused by TMZ. Studies have shown that downregulation of glutathione (GSH) in cells can inhibit the WNT / β-catenin signaling pathway and thus inhibit the expression of MGMT.

[0004] In addition, while TMZ produces diazomethane, another metabolite, 5-amino-imidazole-4-amide (AICA), will eventually induce DNA repair through a series of cascade reactions catalyzed by hypoxanthine phosphoribosyltransferase 1 (HPRT1). 6-Mercaptopurine (6-MP) is a potent HPRT1 inhibitor that can inhibit the DNA repair process caused by AICA.

[0005] Iron phosphide (FeP) is a transition metal phosphide with low cost and excellent comprehensive performance. It has good biosafety as a nanomedicine. Since non-metallic phosphorus and transition metal iron both have multiple valence states, FeP can realize the cycle between multiple valence states.2+ Can mediate the Fenton reaction to form hydroxyl radicals, Fe 3+ It can react with reducing substances, deplete GSH in cells, downregulate the expression of glutathione peroxidase 4 (GPX4) and enhance lipid peroxidation, leading to enhanced ferroptosis.

[0006] Exosomes are a type of extracellular vesicles with a diameter of 30 to 150 nm. Almost all cells can secrete exosomes. Exosomes are important mediators of intercellular signaling and potential drug delivery carriers. Microglia are the main immune cells in the central nervous system. The exosomes they secrete can not only pass through the blood-brain barrier, but also change the content of exosomes by regulating the polarization state of microglia to develop new treatment strategies. FeP nanodrugs coated with microglia-derived exosomes can cross the blood-brain barrier and be delivered to tumor tissues in a targeted manner, thereby improving the accuracy of treatment and reducing damage to healthy tissues.

[0007] FeP nanoparticles have great application potential in tumor treatment. However, single FeP nanoparticles not only have a single effect and low efficiency, but also cannot reach the lesion. In view of this, it is necessary to prepare a surface functionalized FeP nanoparticle and design an optimized bionic nanodrug to address the problems existing in the treatment of brain glioma. Summary of the invention

[0008] Problem that the invention aims to solve

[0009] The present invention aims to provide a surface functionalized iron phosphide nanoparticle and a nanomedicine containing the same, and also provides a preparation method thereof and use thereof in the treatment of tumors (especially drug-resistant tumors). After surface modification, the iron phosphide nanoparticle not only has efficient photothermal conversion capability, but can also significantly reduce the glutathione concentration level and MGMT protein expression level in tumor cells and inhibit HPRT1 protein activity. The nanomedicine can penetrate the blood-brain barrier and deliver the drug to tumor tissue in a targeted manner, thereby reducing damage to healthy tissues.

[0010] Solutions for solving problems

[0011] In a first aspect, the present invention provides a method for preparing surface functionalized iron phosphide nanoparticles, comprising the following steps:

[0012] (1) using iron phosphide nanoparticles and molecules containing thiol groups and other groups that can coordinate with iron to obtain surface thiol-modified iron phosphide nanoparticles;

[0013] (2) reacting the surface-thiolated iron phosphide nanoparticles obtained in step (1) with an active ingredient containing a thiol group to obtain;

[0014] Wherein, the active ingredient containing a thiol group is a small molecule drug containing a thiol group or a thiolated nucleic acid; preferably, the small molecule drug containing a thiol group is 6-mercaptopurine.

[0015] Preferably, the iron phosphide nanoparticles are prepared by chemical vapor deposition or organic solution phase reaction.

[0016] Preferably, in step (1), the iron phosphide nanoparticles and molecules containing thiol groups and other groups that can coordinate with iron undergo coordination exchange to obtain the surface thiol-modified iron phosphide nanoparticles.

[0017] Preferably, the molecule containing a thiol group and other groups that can coordinate with iron is 2,3-dimercaptosuccinic acid.

[0018] Preferably, step (1) is: adjusting the pH of the aqueous solution of the molecules containing thiol groups and other groups that can coordinate with iron to 9-11, dripping it into the dispersion of the iron phosphide nanoparticles, ultrasonicating or stirring, centrifuging, washing, and freeze-drying to obtain surface thiol-modified iron phosphide nanoparticles.

[0019] More preferably, the concentration of the aqueous solution containing thiol and other molecules that can coordinate with iron is 10-50 mg mL -1 The concentration of the dispersion of the iron phosphide nanoparticles is 1 to 10 mg mL -1 .

[0020] More preferably, the iron phosphide nanoparticles are prepared by chemical vapor deposition, and the dispersant in the dispersion of the iron phosphide nanoparticles is water; or, the iron phosphide nanoparticles are prepared by organic solution phase reaction, and the dispersant in the dispersion of the iron phosphide nanoparticles is tetrahydrofuran or chloroform.

[0021] Preferably, in step (2), the small molecule drug containing a thiol group is 6-mercaptopurine, and the 6-mercaptopurine is oxidized to form a dimer, which is reacted with the surface thiol-functionalized iron phosphide nanoparticles obtained in step (1) under the protection of an inert gas, and then centrifuged, washed, and freeze-dried to obtain surface functionalized iron phosphide nanoparticles.

[0022] More preferably, the mass ratio of the 6-mercaptopurine to the surface-thiolated iron phosphide nanoparticles is (0.5-1):1, preferably 1:1.

[0023] More preferably, the reaction is carried out at room temperature.

[0024] More preferably, the reaction time is 24 to 48 hours.

[0025] In a second aspect, the present invention provides a surface functionalized iron phosphide nanoparticle, which is prepared by the preparation method described in the first aspect.

[0026] Preferably, the size of the surface functionalized iron phosphide nanoparticles is 1 to 300 nm.

[0027] More preferably, the iron phosphide nanoparticles are prepared by chemical vapor deposition, and the size of the surface functionalized iron phosphide nanoparticles prepared using the iron phosphide nanoparticles is 200-300 nm, preferably 244.01±15.93 nm, or the iron phosphide nanoparticles are prepared by organic solution phase reaction, and the size of the surface functionalized iron phosphide nanoparticles prepared using the iron phosphide nanoparticles is 2-10 nm, preferably 6.46±2.82 nm.

[0028] In a third aspect, the present invention provides a nanomedicine, which is composed of the surface functionalized iron phosphide nanoparticles described in the second aspect and microglial membranes or microglial exosomes coating the surface functionalized iron phosphide nanoparticles.

[0029] Preferably, the nanodrug is a brain-targeted nanodrug.

[0030] Preferably, the microglial cell membrane or microglial exosomes are derived from primary microglial cells or one or more of the microglial cell lines BV2, N9, HMC3, HMO6 and C8-B4.

[0031] Preferably, the size of the nano drug is 1 to 300 nm.

[0032] More preferably, the iron phosphide nanoparticles are prepared by chemical vapor deposition, and the size of the nanomedicine prepared using the iron phosphide nanoparticles is 200-300 nm, preferably 263.33±8.01 nm, or the iron phosphide nanoparticles are prepared by organic solution phase reaction, and the size of the nanomedicine prepared using the iron phosphide nanoparticles is 5-50 nm, preferably 20.95±1.64 nm.

[0033] In a fourth aspect, the present invention provides a method for preparing the nanodrug described in the third aspect, comprising the following steps: mixing the microglia membrane or microglia exosomes and the surface functionalized iron phosphide nanoparticles, and extruding through a liposome extruder to obtain the nanodrug.

[0034] Preferably, the pore sizes of the filter membranes of the liposome extruder are 400 nm, 200 nm and 100 nm respectively.

[0035] In a fifth aspect, the present invention provides a pharmaceutical composition comprising the nanodrug described in the third aspect and at least one additional anti-tumor drug.

[0036] Preferably, the pharmaceutical composition comprises the nanodrug described in the third aspect and an additional anti-tumor drug.

[0037] More preferably, the antitumor drug is an alkylating agent antitumor drug, preferably temozolomide.

[0038] In a sixth aspect, the present invention provides use of the surface functionalized iron phosphide nanoparticles described in the second aspect, the nanomedicine described in the third aspect, or the pharmaceutical composition described in the fifth aspect in the preparation of a drug for treating tumors.

[0039] Preferably, the tumor is a glioma.

[0040] More preferably, the tumor is a drug-resistant glioma.

[0041] More preferably, the tumor is a temozolomide-resistant glioma.

[0042] Effects of the Invention

[0043] The present invention can significantly improve the efficacy of tumors (especially TMZ-resistant tumors) by modifying the surface of iron phosphide nanoparticles or further preparing nanomedicines, thereby providing a new idea for the treatment of drug-resistant tumors, reversing tumor resistance and reducing the generation of drug resistance. Specifically, the present invention has the following beneficial effects:

[0044] (1) The present invention is the first to use iron phosphide nanoparticles as biopharmaceutical carriers for tumor treatment. After surface modification (surface thiolization and connection with active ingredients containing thiol groups, such as 6-MP), or further being made into nanomedicines, the iron phosphide nanoparticles can significantly reduce the concentration level of glutathione and the expression level of MGMT protein in tumor cells, while inhibiting the protein activity of HPRT1, thereby inhibiting the DNA repair process in tumor cells;

[0045] (2) The iron phosphide nanoparticles of the present invention, after surface modification or further processed into nanomedicine, have high-efficiency light-to-heat conversion performance at 0.8 W cm -2 Under 808nm laser irradiation, it has a selective killing effect on drug-resistant brain glioma cells, can significantly improve the survival rate of TMZ-resistant mice, and has a significant anti-tumor effect; in addition, it can induce tumor immunogenic death, stimulate a strong immune response, and resist tumor recurrence;

[0046] (3) The iron phosphide nanoparticles of the present invention, after surface modification or further being made into nanomedicines, have a strong ability to generate hydroxyl radicals, which can further promote ferroptosis of tumor cells;

[0047] (4) The iron phosphide nanoparticles of the present invention, after surface modification or further being made into nanomedicines, have no obvious hemolytic behavior and cytotoxicity and have good biocompatibility and safety;

[0048] (5) The nanomedicine of the present invention uses microglia-derived exosomes for camouflage, which can mediate the nanoparticles therein to cross the blood-brain barrier and accumulate in the tumor site in a targeted manner, thereby providing treatment accuracy, thereby reducing damage to healthy tissues and reducing adverse reactions;

[0049] (6) The iron phosphide nanoparticles of the present invention, after surface modification or further being made into nanomedicines, have good dispersibility and stability in various aqueous solutions;

[0050] (7) The preparation method of the present invention is simple, low-cost, mild in conditions, has a small particle size, and can be mass-produced or industrialized. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 A is a transmission electron microscopy image of FeP nanoparticles prepared in Example 1;

[0052] Figure 1 B is the transmission electron microscopy image of FeP-MP@Exo prepared in Example 7;

[0053] Figure 1 C is a transmission electron microscopy image of FeP nanoparticles prepared in Example 2;

[0054] Figure 1 D is the transmission electron microscopy image of FeP-MP@Exo prepared in Example 8;

[0055] Figure 2 The XRD patterns of the Fe2O3 nanoparticles and the FeP nanoparticles prepared in Example 1;

[0056] Figure 3 This is the XPS graph of the FeP nanoparticles prepared in Example 1;

[0057] Figure 4 is the XRD pattern of FeP nanoparticles prepared in Example 2;

[0058] Figure 5 A is the Zeta potential measurement result of the FeP nanoparticles prepared in Example 1, the FeP-SH nanoparticles prepared in Example 3, the FeP-MP nanoparticles prepared in Example 5, the exosomes (Exo) in Example 7, and the FeP-MP@Exo nanodrug prepared in Example 7;

[0059] Figure 5B is the hydrodynamic diameter measurement result of the FeP nanoparticles prepared in Example 1, the FeP-SH nanoparticles prepared in Example 3, the FeP-MP nanoparticles prepared in Example 5, and the FeP-MP@Exo nanodrug prepared in Example 7;

[0060] Figure 6 A is the infrared spectrum measurement results of FeP nanoparticles prepared in Example 1, FeP-SH nanoparticles prepared in Example 3, DMSA, FeP-MP nanoparticles prepared in Example 5, and 6-MP;

[0061] Figure 6 B is the infrared spectroscopic measurement results of FeP nanoparticles prepared in Example 2, FeP-SH nanoparticles prepared in Example 4, DMSA, FeP-MP nanoparticles prepared in Example 6, and 6-MP;

[0062] Figure 7 Zeta potential measurement results of FeP nanoparticles prepared in Example 2, FeP-SH nanoparticles prepared in Example 4, FeP-MP nanoparticles prepared in Example 6, exosomes (Exo) in Example 8, FeP@Exo prepared in Comparative Example 1, and FeP-MP@Exo nanomedicine prepared in Example 8;

[0063] Figure 8 A is the FeP-MP@Exo aqueous solution prepared in Example 7 at 0.8 W cm -2 Temperature rise and fall curves under 808nm laser irradiation;

[0064] Figure 8 B is a test diagram of the photothermal conversion stability of FeP-MP@Exo prepared in Example 7;

[0065] Fig. 9 A is the absorption intensity results of four mixed solutions of TMB+H2O2, TMB+FeP, H2O2+FeP, and TMB+H2O2+FeP at 350-720nm;

[0066] Fig. 9 B is the paramagnetic resonance spectrum of hydroxyl radicals generated by FeP nanoparticles prepared in Example 1;

[0067] Fig.10 The concentration change of reduced glutathione in the solution after the FeP nanoparticles prepared in Example 1 were treated;

[0068] Fig.11 A is the change in the concentration of reduced glutathione in the cell after being treated with the FeP nanoparticles in Example 1, the FeP-MP nanoparticles in Example 5, and the FeP-MP@Exo in Example 7;

[0069] Fig.11 B is the change in the concentration of reduced glutathione in the cells after being treated with the FeP nanoparticles in Example 2, the FeP-MP nanoparticles in Example 6, and the FeP-MP@Exo in Example 8;

[0070] Fig.12 A is the cell viability determination result of the FeP-MP@Exo nanomedicine prepared in Example 7;

[0071] Fig.12 B is the cell viability determination result of the FeP-MP@Exo nanomedicine prepared in Example 8;

[0072] Fig.13 The hemolysis rate result of FeP-MP@Exo prepared in Example 7;

[0073] Fig.14 A shows the changes in MGMT protein expression in U87 cells after treatment with various drugs;

[0074] Fig.14 B shows the changes in MGMT protein expression in T98G cells after treatment with various drugs;

[0075] Fig.15 The results of cell survival rate under different concentrations of FeP-MP@Exo;

[0076] Fig.16 The results are for the cell survival rate of U87TR in different treatment groups;

[0077] Fig.17 A is a schematic diagram of the preparation of FeP-SH-Cy3;

[0078] Fig.17 B is the fluorescence intensity result of FeP-SH nanoparticles prepared in Example 3 and FeP-SH-Cy3 prepared therefrom;

[0079] Fig.17 C is the fluorescence intensity result of FeP-SH nanoparticles prepared in Example 4 and FeP-SH-Cy3 prepared therefrom;

[0080] Fig.18 The accumulation of FeP-SH-Cy3 and FeP-SH-Cy3@Exo in U87TR cells;

[0081] Fig.19 Experimental effects of ROS generation in GL261TR cells;

[0082] Fig. 20 is the result of MDA content determination;

[0083] Fig.21 Results are for GPX4 protein expression levels;

[0084] Fig. 22 is the expression level of PTGS2 encoding cyclooxygenase 2;

[0085] Fig.23 is the exposure effect of CRT on the cell surface in GL261TR cells;

[0086] Fig.24 A is the result of HMGB1 level determination;

[0087] Fig.24 B is the result of ATP level measurement;

[0088] Fig.25 The survival rate of each group of mice in the in vivo treatment effect evaluation experiment was performed. DETAILED DESCRIPTION

[0089] Various exemplary embodiments, features and aspects of the present invention will be described in detail below. The word "exemplary" used here means "used as an example, embodiment or illustrative". Any embodiment described here as "exemplary" is not necessarily interpreted as being superior or better than other embodiments.

[0090] In addition, in order to better illustrate the present invention, numerous specific details are provided in the following specific embodiments. It should be understood by those skilled in the art that the present invention can be implemented without certain specific details. In other examples, methods, means, equipment and steps well known to those skilled in the art are not described in detail in order to highlight the subject matter of the present invention.

[0091] Unless otherwise stated, the units used in this specification are all international standard units, and the numerical values ​​and numerical ranges appearing in the present invention should be understood to include the inevitable systematic errors in industrial production.

[0092] In this specification, the word "may" means both performing a certain process and not performing a certain process.

[0093] In this specification, the references to "some specific / preferred embodiments", "other specific / preferred embodiments", "embodiments", etc., mean that the specific elements (e.g., features, structures, properties and / or characteristics) described in connection with the embodiments are included in at least one embodiment described herein, and may or may not exist in other embodiments. In addition, it should be understood that the elements may be combined in various embodiments in any suitable manner.

[0094] In this specification, the numerical range expressed using "a numerical value A to a numerical value B" means a range including the endpoints numerical values ​​A and B.

[0095] In this specification, when "normal temperature" or "room temperature" is used, the temperature may be 15°C to 30°C, for example, 20°C.

[0096] In this specification, "FeP nanoparticles" or "FeP" refers to iron phosphide nanoparticles.

[0097] In the present specification, "FeP-SH nanoparticles", "FeP-SH" or "FeP-SH nanoparticles" all refer to iron phosphide nanoparticles with surface thiols.

[0098] In the present specification, "FeP-MP nanoparticles", "FeP-MP" or "FeP-6-MP" refers to functionalized iron phosphide nanoparticles obtained by attaching 6-MP to surface thiol-modified iron phosphide nanoparticles.

[0099] In this specification, "FeP-MP@Exo", "FeP-6-MP@Exo", "Exo@FeP-6-MP" or "FeP-6-MP-Exo" refers to the nanomedicine obtained by encapsulating the functionalized iron phosphide nanoparticles of the present invention in exosomes.

[0100] After extensive research, the inventors found that FeP nanoparticles have efficient photothermal conversion capabilities. The heat energy generated under external light source irradiation can kill cancer cells and induce immunogenic cell death of tumors, thereby stimulating a strong immune response, attacking remaining or distant tumor cells, and resisting tumor recurrence. Therefore, FeP nanoparticles have great application potential in tumor treatment. The present invention uses FeP nanoparticles as a biopharmaceutical carrier for tumor treatment for the first time to cope with the challenges of temozolomide resistance in traditional treatment of tumors (especially gliomas).

[0101] The mechanism by which the nanomedicine of the present invention achieves reversal of tumor (especially brain glioma) drug resistance is: on the one hand, by depleting glutathione, inhibiting the WNT / β-catenin signaling pathway, and reducing the expression level of MGMT protein; on the other hand, releasing 6-MP in situ, inhibiting the activity of HPRT1 protein, and increasing the sensitivity of brain glioma to TMZ.

[0102] In addition, the present invention also builds a platform for adjusting tumor treatment plans / preparing different anti-tumor drugs. The platform is scalable and can connect FeP nanoparticles with other thiol-containing small molecule drugs or thiol-containing nucleic acids according to actual needs, thereby achieving flexible adjustment of treatment plans and efficient synergistic treatment.

[0103] <Method for preparing surface functionalized FeP nanoparticles>

[0104] The present invention provides a method for preparing surface functionalized iron phosphide nanoparticles, which comprises the following steps:

[0105] (1) using iron phosphide nanoparticles and molecules containing thiol groups and other groups that can coordinate with iron to obtain surface thiol-modified iron phosphide nanoparticles;

[0106] (2) reacting the surface-thiolated iron phosphide nanoparticles obtained in step (1) with an active ingredient containing a thiol group to obtain;

[0107] Wherein, the active ingredient containing thiol groups is a small molecule drug containing thiol groups or a thiol-modified nucleic acid.

[0108] In some specific embodiments, the small molecule drug containing a thiol group is 6-mercaptopurine.

[0109] In the present invention, the molecules containing thiol groups and other groups that can coordinate with iron, the active ingredients containing thiol groups, the small molecule drugs containing thiol groups or the thiolated nucleic acids all include their isomers (such as tautomers). For example, the small molecule drugs containing thiol groups can be 6-mercaptopurine Tautomer

[0110] In some specific embodiments, the iron phosphide nanoparticles are prepared by chemical vapor deposition or organic solution phase reaction.

[0111] In some specific embodiments, the iron phosphide nanoparticles are prepared by chemical vapor deposition. NaH2PO2, as a representative phosphorus source for preparing FeP nanoparticles by chemical vapor deposition, can decompose and release PH3 when heated in a tube furnace, and PH3 gas can directly react with precursors such as iron-based oxides or iron-based hydroxides.

[0112] In some specific embodiments, the raw materials of the chemical vapor deposition method are iron-based oxide or iron-based hydroxide nanoparticles and sodium hypophosphite or its hydrate.

[0113] In some specific embodiments, the diameter of the iron-based oxide or iron-based hydroxide nanoparticles is 10 to 100 nm, preferably 20 to 50 nm, such as 25 nm, 30 nm, 35 nm, 40 nm, etc.

[0114] In some preferred embodiments, the iron-based oxide nanoparticles are α-Fe2O3 nanoparticles.

[0115] In some specific embodiments, the steps of the chemical vapor deposition method include: grinding and mixing iron-based oxide or iron-based hydroxide nanoparticles and sodium hypophosphite or its hydrate, heating to 350-420°C under the protection of an inert gas, keeping the temperature for 2-4 hours, cooling, grinding, adding water, ultrasonicating, centrifuging, washing, and freeze-drying to obtain the iron phosphide nanoparticles.

[0116] In some preferred embodiments, the mass ratio of the iron-based oxide or iron-based hydroxide nanoparticles to the sodium hypophosphite or its hydrate is 1:(5-10), preferably 1:(5-7).

[0117] In some preferred embodiments, the hydrate of sodium hypophosphite is sodium hypophosphite monohydrate.

[0118] In some preferred embodiments, the heating rate is 2-3°C min -1 , preferably 3℃min -1 .

[0119] In some preferred embodiments, the temperature is raised to 380-420°C, preferably 390-410°C.

[0120] In some preferred embodiments, the incubation period is 2 to 3 hours, preferably 3 hours.

[0121] In some preferred embodiments, the temperature is lowered to room temperature.

[0122] In some preferred embodiments, the washing is washing with water, preferably washing with water 3 to 5 times.

[0123] In some preferred embodiments, the water is deionized water.

[0124] In some preferred embodiments, the lyophilization is followed by grinding. The grinding step after lyophilization is not a critical step, and its main purpose is to make the subsequent characterization and testing more uniform and dispersed, so the iron phosphide nanoparticles can be preserved after grinding.

[0125] In some specific embodiments, the iron-based oxide and iron-based hydroxide nanoparticles can be synthesized by hydrothermal method, preferably using FeCl3·6H2O as the iron source. Taking the synthesis of α-Fe2O3 nanoparticles as an example, FeCl3·6H2O, Na2SO4 and NaH2PO4·H2O are fully dissolved in water, hydrothermally treated at 180-200°C for 12-24h, centrifuged, washed, and dried to obtain α-Fe2O3 nanoparticles. In addition, α-Fe2O3 nanoparticles can also be purchased commercially.

[0126] In other specific embodiments, the iron phosphide nanoparticles are prepared by an organic solution phase reaction.

[0127] In some specific embodiments, the raw materials for the organic solution phase reaction are ferric acetylacetonate and trialkylphosphine.

[0128] In some specific embodiments, the solvent for the organic solution phase reaction is oleylamine.

[0129] In some preferred embodiments, the trialkylphosphine is tri-n-octylphosphine.

[0130] In some preferred embodiments, in the organic solution phase reaction, the concentration of ferric acetylacetonate is not higher than 300mM. In the organic solution phase reaction, ferric acetylacetonate can form iron nanoparticles, and the temperature, time and material concentration of this reaction all can affect the size of nanoparticles formed. In this reaction, the concentration of ferric acetylacetonate is limited to not higher than 300mM, if the concentration is too high, the nanoparticle size formed may be enlarged, and the phosphating of iron nanoparticles is difficult to carry out.

[0131] In some specific embodiments, the step of the organic solution phase reaction includes: dispersing ferric acetylacetonate in oleylamine, maintaining the temperature at 100-150°C for 15-30 minutes (for example, maintaining the temperature at 120°C for 0.5 hours) under the protection of an inert gas, slowly adding trialkylphosphine, and heating the temperature to 330-385°C, reacting for 2-5 hours, cooling, adding an alcohol solvent, centrifuging, washing, and freeze-drying to obtain the iron phosphide nanoparticles.

[0132] In some preferred embodiments, the molar ratio of the trialkylphosphine to the ferric acetylacetonate is (3-5):1.

[0133] In some preferred embodiments, the temperature is raised to 330-350°C, preferably 340-350°C.

[0134] In some preferred embodiments, the reaction lasts for 2 to 4 hours, preferably 2 to 3 hours.

[0135] In some preferred embodiments, the temperature is lowered to room temperature.

[0136] In some preferred embodiments, the alcohol solvent is ethanol or isopropanol.

[0137] In some preferred embodiments, the amount of the alcohol solvent added is 2 to 3 times the volume of the reaction solution.

[0138] In some preferred embodiments, the washing is washing with chloroform or ethanol, preferably 3 to 5 times.

[0139] In some specific embodiments, in step (1), the iron phosphide nanoparticles and molecules containing thiol groups and other groups that can coordinate with iron can obtain the surface thiol-modified iron phosphide nanoparticles through coordination exchange.

[0140] In some preferred embodiments, the molecule containing a thiol group and other groups that can coordinate with iron is 2,3-dimercaptosuccinic acid.

[0141] In some specific embodiments, step (1) specifically comprises: adjusting the pH of the aqueous solution of the molecules containing thiol groups and other groups that can coordinate with iron to 9-11, dropping the aqueous solution into the dispersion of the iron phosphide nanoparticles, ultrasonicating or stirring, centrifuging, washing, and freeze-drying to obtain surface thiol-modified iron phosphide nanoparticles.

[0142] In some preferred embodiments, the concentration of the aqueous solution of the molecule containing thiol and other groups that can coordinate with iron is 10-50 mg mL -1 The concentration of the dispersion of the iron phosphide nanoparticles is 1 to 10 mg mL -1 .

[0143] In some specific embodiments, the iron phosphide nanoparticles are prepared by chemical vapor deposition, and the dispersant in the dispersion of the iron phosphide nanoparticles is water. In other specific embodiments, the iron phosphide nanoparticles are prepared by organic solution phase reaction, and the dispersant in the dispersion of the iron phosphide nanoparticles is tetrahydrofuran or chloroform.

[0144] In some preferred embodiments, the washing is washing with water, preferably washing with water 3 to 5 times.

[0145] In some preferred embodiments, the water is deionized water.

[0146] In some specific embodiments, in step (2), the small molecule drug containing a thiol group is 6-mercaptopurine, and the 6-mercaptopurine is oxidized to form a dimer, which is reacted with the surface thiol-modified iron phosphide nanoparticles obtained in step (1) (e.g., a disulfide bond exchange reaction) under the protection of an inert gas, and then centrifuged, washed, and freeze-dried to obtain surface functionalized iron phosphide nanoparticles.

[0147] In some preferred embodiments, the mass ratio of the 6-mercaptopurine to the surface-thiolated iron phosphide nanoparticles is (0.5-1):1, preferably 1:1.

[0148] In some preferred embodiments, the reaction is carried out at room temperature.

[0149] In some preferred embodiments, the reaction time is 24 to 48 hours, preferably 24 to 36 hours.

[0150] In some preferred embodiments, the 6-mercaptopurine is oxidized by iodine to form a dimer.

[0151] In some preferred embodiments, the washing is washing with water, preferably washing with water 3 to 5 times.

[0152] In some preferred embodiments, the water is deionized water.

[0153] <Surface functionalized FeP nanoparticles>

[0154] The present invention provides a surface functionalized iron phosphide nanoparticle, which is prepared by the above-mentioned <method for preparing surface functionalized FeP nanoparticle>.

[0155] In some embodiments, the surface-functionalized iron phosphide nanoparticles have a size of 1 to 300 nm.

[0156] In some specific embodiments, the iron phosphide nanoparticles are prepared by chemical vapor deposition, and the size of the surface functionalized iron phosphide nanoparticles prepared using the iron phosphide nanoparticles is 200-300 nm (e.g., 210 nm, 220 nm, 230 nm, 240 nm, 250 nm, 260 nm, 270 nm, 280 nm, 290 nm, etc.), preferably 244.01±15.93 nm.

[0157] In other specific embodiments, the iron phosphide nanoparticles are prepared by organic solution phase reaction, and the size of the surface functionalized iron phosphide nanoparticles prepared using the iron phosphide nanoparticles is 2 to 10 nm (e.g., 3 nm, 4 nm, 5 nm, 6 nm, 7 nm, 8 nm, 9 nm, etc.), preferably 6.46±2.82 nm.

[0158] <Nanomedicine>

[0159] The present invention provides a nanomedicine comprising the above-mentioned <surface functionalized iron phosphide nanoparticles> and microglial cell membranes or microglial cell exosomes.

[0160] In some preferred embodiments, the nanomedicine consists of the above-mentioned <surface functionalized iron phosphide nanoparticles> and microglial cell membranes or microglial cell exosomes.

[0161] In some specific embodiments, the nanomedicine is obtained by encapsulating the surface functionalized iron phosphide nanoparticles by the microglial cell membrane or microglial exosomes.

[0162] In some specific embodiments, the nanodrug is a brain-targeted nanodrug.

[0163] In the present invention, the microglial cell membrane or microglial exosomes are derived from primary microglial cells or one or more of the microglial cell lines BV2, N9, HMC3, HMO6 and C8-B4.

[0164] In some embodiments, the size of the nanomedicine is 1 to 300 nm.

[0165] In some specific embodiments, the iron phosphide nanoparticles are prepared by chemical vapor deposition, and the size of the nanomedicine prepared using the iron phosphide nanoparticles is 200-300 nm (for example, 210 nm, 220 nm, 230 nm, 240 nm, 250 nm, 260 nm, 270 nm, 280 nm, 290 nm, etc.), preferably 263.33±8.01 nm.

[0166] In other specific embodiments, the iron phosphide nanoparticles are prepared by organic solution phase reaction, and the size of the nanomedicine prepared using the iron phosphide nanoparticles is 5 to 50 nm (for example, 6 nm, 7 nm, 8 nm, 9 nm, 10 nm, 12 nm, 15 nm, 20 nm, 25 nm, 30 nm, 40 nm, etc.), preferably 20.95±1.64 nm.

[0167] <Method for preparing nanomedicine>

[0168] The present invention provides a method for preparing the above-mentioned nanomedicine, which comprises the following steps:

[0169] The microglial cell membrane or microglial cell exosomes and the surface functionalized iron phosphide nanoparticles are mixed and extruded through a liposome extruder to obtain the mixture.

[0170] In some specific embodiments, the microglial cell membrane or microglial cell exosomes and the surface functionalized iron phosphide nanoparticles are mixed and then extruded through a liposome extruder with filter membrane pore sizes of 400 nm, 200 nm and 100 nm, respectively, to obtain the nanomedicine.

[0171] In some specific embodiments, the number of extrusions is 50 or more times, such as 50 to 100 times.

[0172] In some specific embodiments, the microglial cell membrane or microglial cell exosomes and the surface-functionalized iron phosphide nanoparticles are mixed in a PBS solution.

[0173] <Pharmaceutical Composition>

[0174] The present invention provides a pharmaceutical composition comprising the above-mentioned <nano drug> and at least one additional anti-tumor drug.

[0175] In some specific embodiments, the pharmaceutical composition comprises the above-mentioned <nanomedicine> and an additional anti-tumor drug.

[0176] In some specific embodiments, the anti-tumor drug is an alkylating anti-tumor drug, such as temozolomide.

[0177] <Medical Use>

[0178] The present invention also provides medical uses of the above-mentioned <surface functionalized iron phosphide nanoparticles>, the above-mentioned <nanomedicine> or the above-mentioned <drug composition>.

[0179] Specifically, the present invention provides use of the above-mentioned <surface functionalized iron phosphide nanoparticles>, the above-mentioned <nanomedicine> or the above-mentioned <drug composition> in the preparation of a drug for treating tumors.

[0180] In some specific embodiments, the tumor is a glioma.

[0181] In some preferred embodiments, the tumor is a drug-resistant glioma.

[0182] In some more preferred embodiments, the tumor is a temozolomide-resistant glioma.

[0183] <Abbreviation>

[0184] In this manual, the English abbreviations and Chinese full names are as follows:

[0185] Abbreviations Chinese full name Abbreviations Chinese full name 6-MP 6-Mercaptopurine TEER Transendothelial resistance TMZ Temozolomide BBB Blood-brain barrier GSH Glutathione PBS Phosphate buffered saline Exo exosomes GBM Grade IV glioblastoma DMSA Succinic Acid TEM Transmission electron microscopy DMSO Dimethyl sulfoxide XRD X-ray polycrystalline diffraction TMB 3,3',5,5'-Tetramethylbenzidine XPS X-ray Photoelectron Spectroscopy DMPO 5,5-Dimethyl-1-pyrroline N-oxide EDS Energy Dispersive Spectrometer

[0186] Example

[0187] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.

[0188] The α-Fe2O3 nanoparticles used in the embodiments of the present invention are commercially available.

[0189] The present invention proves that the FeP nanoparticles in the embodiment are successfully prepared by transmission electron microscopy (TEM), energy dispersive spectrometer (EDS), X-ray polycrystalline diffraction (XRD) and X-ray photoelectron spectroscopy (XPS).

[0190] The present invention demonstrates the successful modification and exosome encapsulation of the FeP nanoparticles in the examples by transmission electron microscopy (TEM), Zeta potential, infrared spectroscopy and fluorescence spectroscopy.

[0191] Example 1: Preparation of FeP nanoparticles by chemical vapor deposition

[0192] (1) 0.3 g of α-Fe2O3 nanoparticles with an average particle size of 30 nm were mixed with 1.8 g of NaH2PO2·H2O particles, ground into a uniform powder, and heated at 3 °C min-1 under an argon atmosphere. -1 The temperature was heated to 400°C at a rate of 100 °C and maintained for 3 h, and then naturally cooled to room temperature to obtain FeP product;

[0193] (2) Grind the obtained FeP evenly, add 10 mL of deionized water, and sonicate for 2 h to obtain a uniformly distributed FeP solution;

[0194] (3) The FeP solution was centrifuged at 8000 rpm for 10 min, and the precipitate was washed three times with deionized water, freeze-dried, and then ground to obtain FeP nanoparticles.

[0195] The transmission electron microscopy image of the prepared FeP nanoparticles is shown in Figure 1 A, indicating that the size of the FeP nanoparticles is uniform. The XRD patterns of the FeP nanoparticles and the α-Fe2O3 nanoparticles in step (1) are shown in FIG. Figure 2 , XPS of FeP nanoparticles Figure 3 , indicating that FeP nanoparticles have been successfully prepared.

[0196] Example 2: Preparation of FeP nanoparticles by organic solution phase reaction

[0197] (1) Weigh 2 g of ferric acetylacetonate and dissolve it in 20 mL of oleylamine. Add 9 mL of tri-n-octylphosphine while stirring. Heat the reaction system to 120° C. under argon and maintain for 30 min.

[0198] (2) Continue heating to 350°C and maintain for 2 hours;

[0199] (3) After the mixed solution cools to room temperature naturally, add 90 mL of isopropanol;

[0200] (4) Centrifuge at 9000 rpm for 20 min, wash the precipitate three times with ethanol, and freeze-dry to obtain FeP nanoparticles.

[0201] The transmission electron microscopy image of the prepared FeP nanoparticles is shown in Figure 1 C, indicating that the size of FeP nanoparticles is uniform. XRD Figure 4 , indicating that FeP nanoparticles have been successfully prepared.

[0202] Example 3: Surface thiolation of FeP nanoparticles

[0203] (1) Weigh 0.3 g of 2,3-dimercaptosuccinic acid (DMSA), dissolve it in 10 mL of deionized water, and adjust the pH value to 10 with NaOH solution to obtain a DMSA solution;

[0204] (2) Weigh 0.2 g of the FeP nanoparticles in Example 1, dissolve them in 40 mL of deionized water, and disperse them by ultrasonication to obtain a FeP solution;

[0205] (3) 10 mL of FeP solution was mixed with 2.5 mL of DMSA solution, ultrasonicated for 1 h, and then stirred at room temperature for 2 h;

[0206] (4) The mixed solution obtained in step (3) was centrifuged at 8000 rpm for 10 min, the precipitate was washed three times with deionized water, and freeze-dried to obtain FeP-SH nanoparticles.

[0207] The average number of DMSA molecules per FeP-SH nanoparticle was calculated by the following formula:

[0208]

[0209] N DMSA =n DMSA ×N A

[0210]

[0211]

[0212] Where, ε represents the average number of DMSA in each FeP-SH nanoparticle; N DMSA Represents the total amount of DMSA; N FeP represents the total number of FeP-SH nanoparticles. n DMSA Represents the total amount of DMSA, which is calculated based on the amount of S element under the assumption that no disulfide bonds are formed in FeP-SH. The amount of S element is calculated based on the sulfur content (weight percentage) and the mass of FeP-SH nanoparticles. The sulfur content in FeP-SH is 0.484% as measured by an elemental analyzer. V total FeP represents the total volume of FeP-SH nanoparticles; m represents the total mass of FeP-SH nanoparticles; ρ represents the density of FeP-SH nanoparticles, which is approximately 6.07 g / cm 3 V0 represents the volume of a single FeP-SH nanoparticle.

[0213] The above calculations show that in the FeP-SH nanoparticles prepared in this embodiment, the number of thiol groups in each FeP-SH nanoparticle is 2.8×10 5 indivual.

[0214] Example 4: Surface thiolation of FeP nanoparticles

[0215] The step (2) in Example 3 was replaced by: 0.2 g of the FeP nanoparticles in Example 2 was weighed and dissolved in 40 mL of tetrahydrofuran to obtain a FeP solution. The remaining steps remained unchanged to obtain FeP-SH nanoparticles.

[0216] Example 5: Preparation of FeP-MP nanoparticles

[0217] (1) Weigh 90 mg of iodine particles and dissolve them in 3 mL of dimethyl sulfoxide (DMSO) to obtain solution A;

[0218] (2) Weigh 100 mg of 6-MP and dissolve it in 7 mL of DMSO to obtain solution B;

[0219] (3) Solution A was slowly added dropwise to the stirred solution B, and the mixed solution was stirred at room temperature for reaction overnight;

[0220] (4) adding 100 mg of the FeP-SH nanoparticles in Example 3 to the mixed solution after the reaction, and reacting at room temperature for 24 h under an argon atmosphere;

[0221] (5) The mixed solution obtained in step (4) was centrifuged at 8000 rpm for 10 min, the precipitate was washed three times with deionized water, and freeze-dried to obtain FeP-MP nanoparticles.

[0222] Example 6: Preparation of FeP-MP nanoparticles

[0223] Referring to the preparation method of Example 5, only the "FeP-SH nanoparticles" in step (4) are replaced with "FeP-SH nanoparticles in Example 4", and the other steps remain unchanged, to obtain FeP-MP nanoparticles.

[0224] Example 7: Preparation of nanomedicine FeP-MP@Exo

[0225] (1) After culturing HMC3 human microglia in serum-free medium for 24 h, the cell supernatant was collected and centrifuged at 10,000 g for 1 h. After removing the precipitate, the supernatant was centrifuged at 100,000 g for 2 h, and the precipitate was resuspended in 200 μL PBS to obtain an exosome solution;

[0226] (2) Prepare 1 mg mL -110 mL of PBS solution of FeP-MP nanoparticles (prepared in Example 5) was mixed with 50 μL of exosome solution and extruded repeatedly 50 times through a liposome extruder using membranes of 400 nm, 200 nm, and 100 nm, respectively;

[0227] (3) The mixed solution obtained in step (2) was centrifuged at 8000 rpm for 10 min, the precipitate was washed three times with deionized water, and then resuspended in PBS to obtain FeP-MP@Exo, which was stored at -20°C for future use.

[0228] The transmission electron microscopy image of the prepared FeP-MP@Exo is shown in Figure 1 B, showing that the size of FeP-MP@Exo is uniform.

[0229] It was determined that the size of the nanodrug was 263.33±8.01nm.

[0230] Example 8: Preparation of nanomedicine FeP-MP@Exo

[0231] Referring to the preparation method of Example 7, only the "FeP-MP nanoparticles" in step (2) are replaced with "FeP-MP nanoparticles prepared in Example 6" to obtain FeP-MP@Exo.

[0232] The transmission electron microscopy image of the prepared FeP-MP@Exo is shown in Figure 1 D, indicating that the size of FeP-MP@Exo is uniform.

[0233] It was determined that the size of the nanodrug was 20.95±1.64nm.

[0234] Comparative Example 1: Preparation of FeP@Exo

[0235] Referring to the preparation method of Example 7, only the "FeP-MP nanoparticles" in step (2) are replaced with "FeP nanoparticles prepared in Example 1" to obtain FeP@Exo (or Exo@FeP).

[0236] Experimental example

[0237] In the following experimental examples of the present invention, "BSO" is L-buthionine sulfoximine. BSO is a specific inhibitor of γ-glutamylcysteine ​​synthetase and effectively inhibits the biosynthesis of GSH by preventing the connection between glutamate and cysteine.

[0238] The brain glioma cells used in the following experimental examples of the present invention are the following five types: U87 (human natural TMZ-sensitive), U87TR (human induced TMZ-resistant), T98G (human natural TMZ-resistant), GL261 (mouse natural TMZ-sensitive), and GL261TR (mouse induced TMZ-resistant).

[0239] Experimental Example 1: Physicochemical Properties and Structural Characterization

[0240] The FeP nanoparticles prepared in Example 1, the FeP-SH nanoparticles prepared in Example 3, the FeP-MP nanoparticles prepared in Example 5, the exosomes (Exo) in Example 7, and the FeP-MP@Exo nanodrug prepared in Example 7 were measured for Zeta potential and hydrodynamic diameter, and the results were shown in Table 1. Figure 5 A and Figure 5 B.

[0241] The FeP nanoparticles prepared in Example 1, the FeP-SH nanoparticles prepared in Example 3, DMSA, the FeP-MP nanoparticles prepared in Example 5, and 6-MP were measured for infrared spectra, and the results are shown in FIG. Figure 6 A. The FeP nanoparticles prepared in Example 2, the FeP-SH nanoparticles prepared in Example 4, DMSA, the FeP-MP nanoparticles prepared in Example 6, and 6-MP were measured for infrared spectra, and the results are shown in FIG. Figure 6 B.

[0242] The FeP nanoparticles prepared in Example 2, the FeP-SH nanoparticles prepared in Example 4, the FeP-MP nanoparticles prepared in Example 6, the exosomes (Exo) in Example 8, the FeP@Exo prepared in Comparative Example 1, and the FeP-MP@Exo nanomedicine prepared in Example 8 were measured for Zeta potential, and the results are shown in Figure 7 .

[0243] The results showed that the above-mentioned FeP-SH nanoparticles, FeP-MP nanoparticles, FeP-MP@Exo nanodrugs, and FeP@Exo have been successfully prepared, and the prepared nanodrugs have a stable PDI index and have good dispersibility and stability.

[0244] Experimental Example 2: Photothermal Performance Evaluation

[0245] (1) At room temperature, 1 W cm -2 808nm laser irradiated FeP-MP@Exo nanodrug PBS solution for 600s, and infrared thermal imager was used to capture and record the temperature change and thermal image every 15s; as a blank control, PBS solution was irradiated under the same conditions;

[0246] (2) When the temperature rise is basically stable, stop laser irradiation and use an infrared thermal imager to record the temperature change every 15 seconds during the cooling process until the temperature returns to room temperature;

[0247] (3) Calculate the photothermal conversion efficiency using the formula:

[0248]

[0249] Where T max is the equilibrium temperature of the sample solution, T surr Corresponding to the experimental environment temperature. I represents the power density of 808nm laser (1W cm -2 ), A λ Q is the absorbance of the sample solution at 808nm. dis Indicates the heat loss caused by light absorption of the container itself, according to Q dis =(5.4×10 -4 )×I. The value of hS can be calculated using another formula:

[0250]

[0251] Where m is the mass of the sample solution, C water is the specific heat capacity of water 4.2 J g -1 K -1 , τ s is the time constant of the system.

[0252] Combined with the above values, it is calculated that the photothermal conversion efficiency of the FeP-MP@Exo nanodrug prepared in Example 7 is 27.25%, and the photothermal conversion efficiency of the FeP-MP@Exo nanodrug prepared in Example 8 is 31.27%.

[0253] (4) Repeat step (1) and step (2) alternately for at least five times to verify the photothermal stability of the nanodrug.

[0254] The experimental results are shown in Figure 8 , Figure 8 A is the FeP-MP@Exo aqueous solution prepared in Example 7 at 0.8 W cm -2 Temperature rise and fall curve under 808nm laser irradiation, Figure 8 B is a photothermal conversion stability test diagram. From the above results, it can be seen that the FeP-MP@Exo nanomedicine in the present invention has a high photothermal conversion efficiency and good photothermal stability.

[0255] Experimental Example 3: Evaluation of the effect of generating active oxygen

[0256] The activity of FeP nanoparticles (prepared in Example 1) in catalyzing hydrogen peroxide to produce hydroxyl radicals was detected by ultraviolet spectrophotometer. TMB can be oxidized to oxTMB by hydroxyl radicals, and the oxidation product has a significant absorption peak at 652 nm. Deionized water was used to prepare a concentration of 1 mg mL -1The absorption intensity of four mixed solutions of TMB+H2O2, TMB+FeP, H2O2+FeP, and TMB+H2O2+FeP at 350-720nm was measured. The results are shown in Fig. 9 A, indicating that FeP nanoparticles can effectively catalyze hydrogen peroxide to produce hydroxyl radicals.

[0257] Electron paramagnetic resonance (EPR) was used to detect the ability of FeP nanoparticles (prepared in Example 1) to generate hydroxyl radicals. 10 mg of FeP nanoparticles were weighed and dissolved in 1 mL of deionized water. 10 μL of the capture agent DMPO was added to the FeP nanoparticle solution. After mixing evenly, it was aspirated with a capillary and placed in a paramagnetic tube for testing. For comparison, α-Fe2O3 and Fe 2+ The signal strength generated. The experimental results are shown in Fig. 9 B. The results show that the signal intensity generated by FeP nanoparticles is stronger than that of α-Fe2O3 and Fe 2 + The signal intensity generated indicates that FeP nanoparticles have a stronger ability to generate hydroxyl radicals.

[0258] The FeP nanoparticles were replaced with the FeP nanoparticles prepared in Example 2, and the experimental results were similar to the above results.

[0259] Experimental Example 4: Evaluation of the effect on GSH

[0260] In order to verify the GSH consumption capacity of FeP nanoparticles, different concentrations of FeP nanoparticles (prepared in Example 1) were mixed with 200 μg mL -1 After 4 h of reaction at 37°C, the mixed solution was centrifuged and the GSH content in the supernatant was detected according to the instructions of the GSH content determination kit. Fig.10 , indicating that FeP nanoparticles can reduce the concentration of GSH in the solution, and the higher the concentration of FeP nanoparticles, the more significant the effect of reducing the concentration of GSH. The FeP nanoparticles were replaced with the FeP nanoparticles prepared in Example 2, and the experimental results were similar to the above results.

[0261] The concentration is 100 μg mL -1 FeP, 2 μg mL -1 6-MP, 100 μg mL -1 FeP-MP, 100 μg mL -1 FeP-MP@Exo, 2 μg mL -1 BSO, 8 μg mL -1 BSO cell-specific culture medium. U87, U87TR, T98G, GL261, GL261TR cells were cultured at 1×105 The cells were inoculated at a density of 100 μg / mL in a 6-well plate. After culturing for 24 h, the medium was replaced with a complete medium containing drugs and incubated for 24 h. The cells were collected and lysed on ice for 30 min using RIPA lysis buffer. After ultrasonication for 30 s, the supernatant was collected after centrifugation at 10,000 rpm for 5 min. The GSH content in the supernatant was detected using a GSH content assay kit. The results are shown in Fig.11 As shown, Fig.11 The FeP in A is the FeP nanoparticles in Example 1, the FeP-MP is the FeP-MP nanoparticles in Example 5, and the FeP-MP@Exo is the FeP-MP@Exo in Example 7; Fig.11 The FeP in B is the FeP nanoparticles in Example 2, the FeP-MP is the FeP-MP nanoparticles in Example 6, and the FeP-MP@Exo is the FeP-MP@Exo in Example 8.

[0262] Depend on Fig.11 It can be seen that FeP, FeP-MP, and FeP-MP@Exo can significantly reduce the concentration level of GSH in glioma cells, and after FeP nanoparticles are modified into FeP-MP or further encapsulated by exosomes, their ability to reduce the concentration level of GSH is further enhanced, even better than or reaching the effect of BSO in reducing GSH.

[0263] Experimental Example 5: Biocompatibility Evaluation

[0264] The cell validation experiment was carried out in accordance with the relevant provisions of the National Standard of the People's Republic of China GB / T16886.5 (Biological Evaluation of Medical Devices: In Vitro Cytotoxicity Test) and the International Medical Device Biological Evaluation Standard ISO10993-5. The in vitro biosafety of nanomedicines was evaluated using mouse brain microvascular endothelial cells Bend.3 as the research object.

[0265] Take 1 mL of FeP-MP@Exo nanodrug solution and sterilize it with UV for 4 h. Then add Bend.3 special culture medium (containing 10% fetal bovine serum) to prepare concentrations of 10, 50, 100, 200, and 500 μg mL -1 The experimental group culture medium. Select the vigorously growing Bend.3 cells and inoculate them in 96-well plates at about 50,000 cells / well. Add 100 μL of experimental group culture medium of each concentration to each well of the experimental group, add 100 μL of complete culture medium to each well of the control group, and add only complete culture medium to the blank group without adding cells. After placing in a 37°C, 5% CO2 incubator for 6 hours, add 10 μL of CCK8 reagent, and after culturing for 4 hours, use an enzyme reader to measure the absorbance of each well solution at 450nm, according to the calculation formula:

[0266]

[0267] Calculate the cell survival rate. As the concentration of FeP-MP@Exo nanomedicine increases, the cell survival rate of Bend.3 cells does not change significantly. Fig.12 . Fig.12 A is the determination result of FeP-MP@Exo nanomedicine prepared in Example 7, with concentrations of 10, 50, 100, 200, and 500 μg mL -1 The cell survival rates were 86.36±1.15%, 80.93±3.07%, 84.13±3.73%, 90.19±6.30% and 80.04±22.19%, respectively. Fig.12 B is the measurement result of FeP-MP@Exo nanomedicine prepared in Example 8, the cell survival rate is Fig.12 A is higher. The above results show that FeP-MP@Exo nanomedicine has no obvious cytotoxicity and has good biosafety.

[0268] Experimental Example 6: In vitro hemolysis rate evaluation

[0269] Fresh mouse red blood cells were taken and diluted to 2.5% with physiological saline. A series of FeP-MP@Exo solutions were prepared according to Example 7, with concentrations of 50, 100, 250, 500, and 1000 μg mL -1 , added to the red blood cell solution and incubated at 37°C for 3h. Physiological saline and deionized water were used as negative and positive control samples, respectively. After the incubation, the solution was centrifuged at 1500g for 5min, and the absorbance of the supernatant was detected at 450nm by a UV spectrophotometer. The hemolysis rate was calculated according to the following formula:

[0270]

[0271] The experimental results are shown in Fig.13 The hemolysis rate of FeP-MP@Exo solution at each concentration was low, even 0, and basically did not exceed 5%. When the concentration of FeP-MP@Exo solution was as high as 1000 μg mL -1 The hemolysis rate did not exceed 10%, which shows that FeP-MP@Exo has basically no hemolytic behavior and has good biosafety.

[0272] Experimental Example 7: Evaluation of the effect on MGMT protein expression

[0273] The concentration is 100 μg mL -1 FeP, 2 μg mL -1 6-MP, 100 μg mL -1 FeP-MP@Exo, 8 μg mL -1BSO cell-specific culture medium (FeP is the FeP nanoparticles in Example 1, and FeP-MP@Exo is the FeP-MP@Exo in Example 7). U87, U87TR, and T98G cells were cultured at 1×10 5 The cells were inoculated at a density of 1000 μg / mL in a 6-well plate. After culturing for 24 hours, the medium was replaced with complete medium containing drugs and incubated for 24 hours. The cells were collected and lysed on ice for 30 minutes with RIPA lysis buffer containing protease inhibitors. After ultrasonication for 30 seconds, the supernatant was collected after centrifugation at 10,000 rpm for 10 minutes. The total protein concentration was determined using a BCA kit, and β-actin was used as an internal reference protein. The expression level of MGMT protein in each sample was detected by Western Blot.

[0274] The experimental results are shown in Fig.14 , Fig.14 A is the result of the expression change of MGMT protein in U87 cells. Fig.14 B shows the expression changes of MGMT protein in T98G cells. Fig.14 It can be seen that both FeP and FeP-MP@Exo can reduce the expression level of MGMT protein in brain glioma cells, and the effect of FeP-MP@Exo is more significant, even better than that of BSO.

[0275] Experimental Example 8: Evaluation of in vitro therapeutic effects

[0276] The vigorously growing U87, U87TR, T98G, GL261, and GL261TR cells were seeded into 96-well plates at a concentration of approximately 5×10 4 After culturing in a 37°C, 5% CO2 incubator for 24 hours, the original culture medium was discarded, and a series of complete culture medium with TMZ concentrations ranging from 100 to 10000 μM was prepared. 100 μL of complete culture medium with each concentration of TMZ was added to each well. After culturing for 12 hours, 10 μL of CCK8 reagent was added to each well. After culturing for another 2 hours, the absorbance of each well at 450 nm was detected with an enzyme marker, and the cell survival rate and half lethal dose IC of each well were calculated. 50 The result is that U87 IC 50 =983.8μM, U87TR IC 50 =4350μM, T98G IC 50 =4312μM, GL261 IC 50 =645μM, GL261TR IC 50 =2351μM.

[0277] The FeP-MP@Exo prepared in Example 7 was sterilized by UV for 4 h, and the concentrations were 0, 50, 75, 100, and 200 μg mL -1The vigorously growing U87, U87TR, T98G, GL261, and GL261TR cells were seeded in 96-well plates at a concentration of approximately 5×10 4 Each well of the experimental group was added with 100 μL of each concentration of culture medium, each well of the control group was added with 100 μL of complete culture medium, and the blank group was added with complete culture medium only without cells. After 6 h of culture, PBS was added to rinse gently for 3 times, and then 100 μL of complete culture medium was added to each well, and then 0.8 W cm -2 , 808nm laser irradiation for 5min. After 6h of incubation, 10μL CCK8 reagent was added to each well. After 2h of incubation, the absorbance of each well at 450nm was detected by an enzyme marker to calculate the cell survival rate. Fig.15 ,exist Fig.15 The darker the color, the lower the survival rate. Fig.15 It can be seen that as the concentration of FeP-MP@Exo increases, the survival rate of each cell gradually decreases. When the concentration of FeP-MP@Exo reaches 100 μg mL -1 When the cells were treated with FeP-MP@Exo, the survival rates of all cells were lower than 50%, indicating that FeP-MP@Exo had a very significant killing effect on TMZ-sensitive or -resistant cells in humans and mice.

[0278] The vigorously growing U87, U87TR, T98G, GL261, and GL261TR cells were seeded in 96-well plates at a concentration of approximately 5×10 4 / well. Prepare 1mM TMZ, 100μg mL -1 The experimental culture medium of FeP-MP@Exo was divided into control group, TMZ treatment group, TMZ+phototherapy group, FeP-MP@Exo group, FeP-MP@Exo+phototherapy group, TMZ+FeP-MP@Exo group and TMZ+FeP-MP@Exo+phototherapy group. After 24 hours of culture, the original culture medium was discarded, and 100 μL of the culture medium of each experimental group was added to each well. After 4 hours of culture, PBS was added to rinse gently 3 times, and then 100 μL of complete culture medium was added to each well. The phototherapy group was treated with 0.8W cm -2 , 808nm laser irradiation for 5min. After 6h of incubation, 10μL CCK8 reagent was added to each well. After 2h of incubation, the absorbance of each well at 450nm was detected with an enzyme marker to calculate the cell survival rate. The cell survival rate results of U87TR are shown in Fig.16 The results of other cells were similar, and the results showed that the TMZ+FeP-MP@Exo+phototherapy group achieved the best therapeutic effect, with cell survival rates below 10%.

[0279] Experimental Example 9: In vitro blood-brain barrier crossing ability assessment

[0280] 1mL 0.1mg mL -1 Add 50 μL of 1 mg mL FeP-SH -1 Cy3-maleimide (solvent is DMSO), ultrasonically mixed in pH 7.4 PBS buffer at room temperature for 2 hours, and centrifuged to obtain fluorescently labeled FeP-SH-Cy3. Fig.17 A is a schematic diagram of the preparation of FeP-SH-Cy3. Fig.17 B is the fluorescence intensity result of FeP-SH nanoparticles prepared in Example 3 and FeP-SH-Cy3 prepared therefrom, Fig.17 C is the fluorescence intensity result of FeP-SH nanoparticles prepared in Example 4 and FeP-SH-Cy3 prepared therefrom. The results show that FeP-SH-Cy3 has been successfully prepared, and also prove the successful thiolation of FeP nanoparticles. The preparation method of FeP-SH-Cy3@Exo refers to the preparation method of FeP-MP@Exo.

[0281] Bend.3 cells were seeded in Transwell chambers at a concentration of approximately 1×10 5 pcs / well, used to construct an in vitro blood-brain barrier model. When TEER exceeds 200Ωcm -2 The in vitro blood-brain barrier model was successfully constructed. U87TR cells were seeded in a 24-well plate, and the culture medium in the Transwell chamber was replaced with 100 μg mL -1 Fresh culture medium of fluorescently labeled FeP-SH-Cy3 and FeP-SH-Cy3@Exo was added. After 8 h of culture, the TEER value was measured to verify the integrity of the BBB in vitro. Flow cytometry and laser confocal microscopy were used to detect the accumulation of FeP-SH-Cy3 and FeP-SH-Cy3@Exo in U87TR cells. The results are shown in Fig.18 As shown, the abscissa represents the Cy3 fluorescence intensity. The results show that the nanoparticles of the present invention (ie, the nanomedicine of the present invention) can smoothly pass through the blood-brain barrier after being coated with exosomes.

[0282] Experimental Example 10: Evaluation of the effect of induced ferroptosis

[0283] The accumulation of intracellular lipid peroxides induces ferroptosis. Prepare experimental group culture medium containing RSL3 (ferroptosis inducer), FeP, 6-MP, and FeP-MP@Exo, and inoculate U87TR, T98G, and GL261TR cells in 6-well plates. After the cells adhere to the wall, replace the culture medium with complete medium containing drugs, incubate for 24 hours, rinse three times with DPBS, and perform the following operations respectively:

[0284] (1) Detection of intracellular ROS generation: Add 10 μM DCFH-DA and incubate at room temperature for 20 min, rinse three times with PBS, and collect cells for fluorescence confocal imaging or flow cytometry detection. The experimental results of GL261TR cells are shown in Fig.19 ,The results showed that the nanomedicine FeP-MP@Exo of the present invention can induce a significant increase in ROS in cells (enhanced green fluorescence), which is consistent with the effect of the standard ferroptosis-inducing drug RSL3.

[0285] (2) Lipid peroxidation detection: Add 10 μM BODIPY 581 / 591C11 working solution, incubate at room temperature for 30 min, wash three times with PBS, and collect cells for fluorescence confocal imaging or flow cytometry detection.

[0286] (3) Malondialdehyde (MDA) content detection: Collect cells, ultrasonically disrupt, centrifuge at 10,000 rpm for 10 minutes, and collect the supernatant. According to the formula in the instructions of the MDA content detection kit, the absorbance of the supernatant was measured at 450, 532 and 600 nm by an ELISA reader to calculate the MDA content. The results are shown in Fig. 20 The results showed that the nanomedicine of the present invention can significantly increase the content of malondialdehyde in each cell, proving that it can significantly induce cell ferroptosis.

[0287] (4) PTGS2 and GPX4 protein expression: The cells were lysed on ice for 30 min using RIPA lysis buffer containing protease inhibitors, and the supernatant was collected after 30 s of sonication and centrifugation at 10,000 rpm for 10 min. The total protein concentration was determined using a BCA kit, and β-actin was used as an internal reference protein. The expression levels of PTGS2 and GPX4 proteins in each sample were detected by Western Blot. The results of GPX4 protein expression levels are shown in Fig.21 The results showed that in the nanomedicine treatment group of the present invention, the GPX4 protein level was significantly downregulated. At the same time, the expression level of PTGS2 encoding cyclooxygenase 2 was Fig. 22 The PTGS2 protein level was significantly upregulated, indicating that the nanodrug FeP-MP@Exo could induce the onset of cellular ferroptosis.

[0288] Experimental Example 11: Evaluation of the effect of inducing immunogenic death

[0289] To evaluate the ability of FeP-MP@Exo to photothermally induce immunogenic cell death (ICD), damage-associated molecular patterns (DAMPs), namely the surface exposure of CRT and the release of HMGB1 and ATP, were first investigated.

[0290] (1) U87TR, T98G, and GL261TR cells were inoculated in glass-bottomed culture dishes and treated with the corresponding culture medium, FeP-MP@Exo, and FeP-MP@Exo combined with light, respectively. After 24 hours, they were washed three times with PBS, and then 4% paraformaldehyde was added and fixed at 4°C for 30 minutes. The cells were washed, blocked with 10% sheep serum, incubated with CRT antibody at 4°C overnight, and then incubated with Alexa Fluor594-conjugated secondary antibody at 37°C for 2 hours. The cells were stained with DAPI and imaged with a fluorescent confocal microscope. The experimental results of GL261TR cells are shown in Figure 2. Fig.23 The results show that FeP-MP@Exo combined with light more significantly induced the exposure of CRT on the cell surface, proving that the nanomedicine of the present invention can induce immunogenic cell death under the condition of combined light.

[0291] (2) U87TR, T98G, and GL261TR cells were grown at 2×10 4 The cells were inoculated in a 96-well plate at a density of 100 / well. After 24 hours, FeP-MP@Exo and FeP-MP@Exo combined with light treatment were performed. The supernatant was collected after 24 hours and centrifuged at 12000g for 10 minutes at 4°C. The HMGB1 level released by cells in the supernatant was then detected using an enzyme-linked immunosorbent assay kit for HMGB1, and the absorbance was measured at a wavelength of 450nm using an enzyme-linked immunosorbent assay. The results are shown in Fig.24 A, indicating that FeP-MP@Exo combined with light treatment can significantly increase the level of HMGB1 released by cells.

[0292] (3) U87TR, T98G, and GL261TR cells were grown at 2×10 4 The cells were inoculated at a density of 1000 / well in a black 96-well plate, and FeP-MP@Exo and FeP-MP@Exo combined with light were treated 24 hours later. The supernatant was collected 24 hours later and centrifuged at 12000g for 10 minutes at 4°C. The ATP level in the supernatant was then detected using an ATP detection kit based on the luciferin-luciferase reaction, and the chemiluminescence of the sample was monitored using an enzyme reader. The results are shown in Fig.24 B, indicating that FeP-MP@Exo combined with light treatment can significantly increase the level of ATP released by cells.

[0293] The above experimental results show that photothermal treatment leads to CRT surface exposure and HMGB1 and ATP release in the three cell lines, which fully proves that the photothermal treatment of the nanomedicine of the present invention can induce immunogenic cell death of tumor cells.

[0294] In vitro bone marrow-derived dendritic cell (BMDC) maturation assessment: BMDCs were isolated from the tibia and femur of BALB / c female mice (8 weeks old) and cultured in 5% FBS-supplemented medium (20 ng mL-1 GM-CSF and 10 ng mL -1 IL-4-containing RMPI 1640 medium was used to induce BMDCs differentiation. U87TR cells were seeded into the upper chamber of the Transwell and cultured overnight, and then treated with PBS, FeP-MP@Exo, and FeP-MP@Exo combined with light. Afterwards, BMDCs (5×10 5 The cells were cultured in the lower chamber of the Transwell for 24 hours. Finally, BMDCs were collected and stained with anti-CD11c, anti-CD80, and anti-CD86, and detected by flow cytometry.

[0295] Experimental Example 12: In vivo therapeutic effect evaluation

[0296] (1) GL261TR-Luc cells (5 μL, 1×10 8 The GL261TR-derived orthotopic TMZ-resistant GBM mouse model was established. Within 3 to 7 days, the tumor-bearing mice were intraperitoneally injected with luciferin substrate (150 mg kg -1 ), after isoflurane anesthesia, the mice were placed in the small animal in vivo imaging system for detection.

[0297] (2) Weigh the mice once before vaccination and once a day thereafter to observe changes in body weight.

[0298] (3) Eight days after modeling, luciferase was injected into the abdomen of mice, and the fluorescence intensity of the mouse brain was observed using a live imaging instrument. The mice were randomly divided into four groups and injected with PBS, TMZ (40 mg kg -1 )、TMZ+FeP@Exo(5mg kg -1 )+NIR、TMZ+FeP-MP@Exo(5mg kg -1 )+NIR, phototherapy using 0.8W cm -2 The mice were irradiated with 808 nm laser for 10 min. All treatments were repeated every three days for a total of 4 treatments. The body weight of the mice was monitored every day, and the tumor volume was monitored by a live imaging system. The survival rate of mice in each group was determined by the Kaplan-Meier method. After the treatment, brain tissues and other major organs of GBM mice were collected, and the tissue morphology was observed by HE staining.

[0299] The results showed that the nanomedicine of the present invention had no damage to the main organs of mice and had good biosafety.

[0300] The survival rate of mice in each group is shown in Fig.25It can be seen that the nanomedicine obtained by coating the surface functionalized iron phosphide nanoparticles of the present invention with exosomes combined with phototherapy can significantly improve the survival rate of TMZ-resistant GBM mice, and is superior to the therapeutic effect of the nanomedicine obtained by coating the iron phosphide nanoparticles with exosomes.

[0301] It should be noted that, although the technical solution of the present invention is introduced with specific examples, those skilled in the art will appreciate that the present invention should not be limited thereto.

[0302] The embodiments of the present invention have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or technical improvements in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.

Claims

1. A method for preparing surface functionalized iron phosphide nanoparticles, comprising the following steps: (1) using iron phosphide nanoparticles and molecules containing thiol groups and other groups that can coordinate with iron to obtain surface thiol-modified iron phosphide nanoparticles; (2) reacting the surface-thiolated iron phosphide nanoparticles obtained in step (1) with an active ingredient containing a thiol group to obtain; Wherein, the active ingredient containing a thiol group is a small molecule drug containing a thiol group or a thiolated nucleic acid; preferably, the small molecule drug containing a thiol group is 6-mercaptopurine.

2. The preparation method according to claim 1, characterized in that: The iron phosphide nanoparticles are prepared by chemical vapor deposition or organic solution phase reaction.

3. The preparation method according to claim 1 or 2, characterized in that: In step (1), the iron phosphide nanoparticles and molecules containing thiol groups and other groups that can coordinate with iron are subjected to coordination exchange to obtain the surface thiol-modified iron phosphide nanoparticles.

4. The preparation method according to any one of claims 1 to 3, characterized in that: The molecule containing thiol and other groups that can coordinate with iron is 2,3-dimercaptosuccinic acid.

5. The preparation method according to any one of claims 1 to 4, characterized in that: Step (1) is: adjusting the pH of the aqueous solution containing the thiol group and other groups that can coordinate with iron to 9-11, dropping it into the dispersion of the iron phosphide nanoparticles, ultrasonicating or stirring, centrifuging, washing, and freeze-drying to obtain the surface thiol-modified iron phosphide nanoparticles; Preferably, the concentration of the aqueous solution containing thiol and other molecules that can coordinate with iron is 10-50 mg / mL -1 The concentration of the dispersion of the iron phosphide nanoparticles is 1 to 10 mg mL -1 ; and / or Preferably, the iron phosphide nanoparticles are prepared by chemical vapor deposition, and the dispersant in the dispersion of the iron phosphide nanoparticles is water; alternatively, the iron phosphide nanoparticles are prepared by organic solution phase reaction, and the dispersant in the dispersion of the iron phosphide nanoparticles is tetrahydrofuran or chloroform.

6. The preparation method according to any one of claims 1 to 5, characterized in that: In step (2), the small molecule drug containing a thiol group is 6-mercaptopurine, and the 6-mercaptopurine is oxidized to form a dimer, which is reacted with the surface thiol-functionalized iron phosphide nanoparticles obtained in step (1) under the protection of an inert gas, and then centrifuged, washed, and freeze-dried to obtain surface functionalized iron phosphide nanoparticles; Preferably, the mass ratio of the 6-mercaptopurine to the surface-thiolated iron phosphide nanoparticles is (0.5-1):1, preferably 1:1; Preferably, the reaction is carried out at room temperature; and / or Preferably, the reaction time is 24 to 48 hours.

7. A surface functionalized iron phosphide nanoparticle, prepared by the preparation method according to any one of claims 1 to 6; Preferably, the size of the surface functionalized iron phosphide nanoparticles is 1 to 300 nm; more preferably, the iron phosphide nanoparticles are prepared by chemical vapor deposition, and the size of the surface functionalized iron phosphide nanoparticles prepared using the iron phosphide nanoparticles is 200 to 300 nm, preferably 244.01±15.93 nm, or the iron phosphide nanoparticles are prepared by organic solution phase reaction, and the size of the surface functionalized iron phosphide nanoparticles prepared using the iron phosphide nanoparticles is 2 to 10 nm, preferably 6.46±2.82 nm.

8. A nanomedicine, comprising the surface functionalized iron phosphide nanoparticles according to claim 7 and microglial cell membranes or microglial cell exosomes coated with the surface functionalized iron phosphide nanoparticles; Preferably, the nanodrug is a brain-targeted nanodrug; Preferably, the microglial cell membrane or microglial exosomes are derived from primary microglial cells or one or more of the microglial cell lines BV2, N9, HMC3, HMO6 and C8-B4; and / or Preferably, the size of the nanomedicine is 1 to 300 nm; more preferably, the iron phosphide nanoparticles are prepared by chemical vapor deposition, and the size of the nanomedicine prepared using the iron phosphide nanoparticles is 200 to 300 nm, preferably 263.33±8.01 nm, or the iron phosphide nanoparticles are prepared by organic solution phase reaction, and the size of the nanomedicine prepared using the iron phosphide nanoparticles is 5 to 50 nm, preferably 20.95±1.64 nm.

9. The method for preparing the nano drug according to claim 8, comprising the following steps: The microglial cell membrane or microglial cell exosomes and the surface functionalized iron phosphide nanoparticles are mixed and extruded through a liposome extruder to obtain the mixture.

10. A pharmaceutical composition comprising the nanodrug according to claim 8 and at least one additional anti-tumor drug, preferably comprising the nanodrug according to claim 8 and one additional anti-tumor drug; Preferably, the antitumor drug is an alkylating agent, preferably temozolomide.

11. Use of the surface functionalized iron phosphide nanoparticles according to claim 7, the nanomedicine according to claim 8 or the pharmaceutical composition according to claim 10 in the preparation of a drug for treating tumors; Preferably, the tumor is a glioma; More preferably, the tumor is a drug-resistant glioma; More preferably, the tumor is a temozolomide-resistant glioma.

Citation Information

Patent Citations

  • Magnetic resonance imaging developing agent with acid environment response function and preparation method thereof

    CN109106955A

  • Double-transition metal phosphide nano material as well as preparation method and application thereof

    CN115120718A

  • Exosome loaded with temozolomide and gold nanoparticles as well as preparation method and application of exosome

    CN117771385A